Retinitis Pigmentosa News and Research RSS Feed - Retinitis Pigmentosa News and Research

Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder. [More]
Researchers compare effectiveness of two stem cell types in treating retinal degeneration

Researchers compare effectiveness of two stem cell types in treating retinal degeneration

By growing two types of stem cells in a "3-D culture" and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing retinal cells. [More]
New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study by researchers at the National Eye Institute (NEI) shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa. [More]
Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for eyes -- the replacement of a faulty gene with a healthy one -- is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people with a genetic disorder that leaves them blind by middle age. [More]
'Bionic eye' improves visual function, quality of life for people with retinitis pigmentosa

'Bionic eye' improves visual function, quality of life for people with retinitis pigmentosa

The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of the device that restores vision in those blinded by a rare, degenerative eye disease. [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
Researchers identify previously unknown gene mutation that causes achromatopsia

Researchers identify previously unknown gene mutation that causes achromatopsia

People with achromatopsia, an inherited eye disorder, see the world literally in black and white. Worse yet, their extreme sensitivity to light makes them nearly blind in bright sunlight. Now, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health System have identified a previously unknown gene mutation that underlies this disorder. [More]
Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

People with achromatopsia, an inherited eye disorder, see the world literally in black and white. Worse yet, their extreme sensitivity to light makes them nearly blind in bright sunlight. Now, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health System have identified a previously unknown gene mutation that underlies this disorder. [More]
Scientist receives $4.9 million CIRM grant to advance work in retinitis pigmentosa

Scientist receives $4.9 million CIRM grant to advance work in retinitis pigmentosa

Shaomei Wang, MD, PhD, a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute, received a $4.9 million grant from the California Institute for Regenerative Medicine to advance her work in retinitis pigmentosa, a type of degenerative retinal disease. [More]
UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial. [More]
Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. [More]
RetroSense Therapeutics receives Luis Villalobos Award

RetroSense Therapeutics receives Luis Villalobos Award

RetroSense Therapeutics, LLC, a Wayne State University start-up biotechnology company, has received the Luis Villalobos Award from the Angel Capital Association, the world's leading professional association for angel investors. [More]
Research reveals stark variation in genetic tests for inherited eye disease in England

Research reveals stark variation in genetic tests for inherited eye disease in England

New research from The University of Manchester published in the Journal of Community Genetics reveals a stark variation in genetic testing services for inherited eye disease in England. [More]

Study shows stark variation in genetic testing services for inherited eye conditions in England

New research from The University of Manchester published in the Journal of Community Genetics reveals a stark variation in genetic testing services for inherited eye disease in England. [More]
Wearable collision warning device may help patients with peripheral vision loss

Wearable collision warning device may help patients with peripheral vision loss

People who have lost some of their peripheral vision, such as those with retinitis pigmentosa, glaucoma, or brain injury that causes half visual field loss, often face mobility challenges and increased likelihood of falls and collisions. [More]
UCSF professor wins Vilcek Prize in Biomedical Science

UCSF professor wins Vilcek Prize in Biomedical Science

Peter Walter was chosen as winner of the Vilcek Prize in Biomedical Science for his pioneering work on how proteins are transported between cellular compartments and for unraveling the components of a regulatory mechanism that cells use to handle stress tied to the aggregation of misshapen proteins. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Researchers discover retina protein crucial for vision

Researchers discover retina protein crucial for vision

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. [More]
Researchers uncover new gene tied to incurable eye disorder

Researchers uncover new gene tied to incurable eye disorder

An exhaustive hereditary analysis of a large Louisiana family with vision issues has uncovered a new gene tied to an incurable eye disorder called retinitis pigmentosa, according to an examination led by scientists at The University of Texas Health Science Center at Houston. [More]

Two UTHealth professors selected as AAAS Fellows for their efforts to prevent blindness

Two professors in the School of Public Health at The University of Texas Health Science Center at Houston - Stephen Daiger, Ph.D., and Robert Hardy, Ph.D. - have been elected to the rank of Fellow in the American Association for the Advancement of Science for their efforts to prevent blindness. [More]
Advertisement
Advertisement